{
    "clinical_study": {
        "@rank": "161259", 
        "brief_summary": {
            "textblock": "RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may\n      help doctors identify biomarkers related to cancer.\n\n      PURPOSE: This clinical trial studies tumor tissue from patients with rhabdomyosarcoma to\n      identify important proteins and biomarkers."
        }, 
        "brief_title": "Biomarkers in Patients With Advanced Rhabdomyosarcoma", 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Rhabdomyosarcoma", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  To investigate whether the expression of a subset of proteins (by\n           immunohistochemistry), known to be involved in the Pax3, Pax7, and Patched-1\n           neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar\n           and embryonal rhabdomyosarcomas.\n\n      OUTLINE: Iimmunohistochemistry is performed for each candidate target (Pax3, Pax7, and\n      Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue\n      microarray analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  8 tissue microarrays (TMA) slides of the following diseases available:\n\n               -  Alveolar rhabdomyosarcoma\n\n               -  Embryonal rhabdomyosarcoma\n\n               -  Anaplastic rhabdomyosarcoma\n\n        PATIENT CHARACTERISTICS:\n\n          -  Not specified\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668095", 
            "org_study_id": "CDR0000738499", 
            "secondary_id": "COG-ARST12B8"
        }, 
        "intervention": [
            {
                "intervention_name": "microarray analysis", 
                "intervention_type": "Genetic"
            }, 
            {
                "intervention_name": "protein expression analysis", 
                "intervention_type": "Genetic"
            }, 
            {
                "intervention_name": "immunohistochemistry staining method", 
                "intervention_type": "Other"
            }, 
            {
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "adult rhabdomyosarcoma", 
            "alveolar childhood rhabdomyosarcoma", 
            "embryonal childhood rhabdomyosarcoma", 
            "previously treated childhood rhabdomyosarcoma", 
            "recurrent adult soft tissue sarcoma", 
            "recurrent childhood rhabdomyosarcoma", 
            "stage III adult soft tissue sarcoma", 
            "stage IV adult soft tissue sarcoma"
        ], 
        "lastchanged_date": "August 18, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/COG-ARST12B8"
        }, 
        "official_title": "Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas", 
        "overall_official": {
            "affiliation": "Oregon Health and Science University", 
            "last_name": "Charles Keller, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668095"
        }, 
        "responsible_party": {
            "name_title": "Peter C. Adamson", 
            "organization": "Children's Oncology Group - Group Chair Office"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Children's Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}